Grant: Engage Grants Program
McMaster University
$25,000.00
Enhanced LSPR sensitivity for OpenSPR detection of therapeutic antibodies and polymer antibody conjugates
EF 2018-19
Résumé
Therapeutic antibodies represent a growing class of drug that are particularly important for cancer immunotherapies. Due to biological transport barriers, many treatments fail due to the lack of antibodies reaching the disease site. Furthermore, large doses of antibodies are commonly administered, which may lead to toxic side effects. Therefore, we are developing an injectable local release system to increase antibody concentrations at the disease site, while decreasing side effects and cost. To accomplish these goals, we need methods to rapidly detect and assess the activity of therapeutic antibodies released from our delivery systems. Nicoya Lifesciences has developed the first commercial instrument, OpenSPR, based on localized surface plasmon resonance (LSPR) biosensing. Compared to other techniques, OpenSPR has a high signal to noise ratios that is amenable to cost effective high throughput analysis. Currently, OpenSPR lacks the sensitivity to detect pico to femtomole amounts of antibodies, which is required for biologically relevant release studies. To this end, we will develop procedures and materials to enhance the LSPR detection of antibodies in the OpenSPR instrument. Because LSPR measures shifts in light absorption due to refractive index changes upon antibody binding to the gold OpenSPR surface, LSPR enhancement will be accomplished by: (1) modifying antibodies with chromophores that absorb visible light; and (2) adding antibody binding peptides modified with chromophores that absorb visible light. The combination of Nicoya's LSPR technology and the Wylie lab's expertise in therapeutic antibodies will result in the development of new LSPR protocols and materials to rapidly analyze dilute antibody solutions.*
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
532019-2018
Name nom
Wylie, Ryan
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Enhanced LSPR sensitivity for OpenSPR detection of therapeutic antibodies and polymer antibody conjugates
Keyword
NSERC
Application summary
Therapeutic antibodies represent a growing class of drug that are particularly important for cancer immunotherapies. Due to biological transport barriers, many treatments fail due to the lack of antibodies reaching the disease site. Furthermore, large doses of antibodies are commonly administered, which may lead to toxic side effects. Therefore, we are developing an injectable local release system to increase antibody concentrations at the disease site, while decreasing side effects and cost. To accomplish these goals, we need methods to rapidly detect and assess the activity of therapeutic antibodies released from our delivery systems. Nicoya Lifesciences has developed the first commercial instrument, OpenSPR, based on localized surface plasmon resonance (LSPR) biosensing. Compared to other techniques, OpenSPR has a high signal to noise ratios that is amenable to cost effective high throughput analysis. Currently, OpenSPR lacks the sensitivity to detect pico to femtomole amounts of antibodies, which is required for biologically relevant release studies. To this end, we will develop procedures and materials to enhance the LSPR detection of antibodies in the OpenSPR instrument. Because LSPR measures shifts in light absorption due to refractive index changes upon antibody binding to the gold OpenSPR surface, LSPR enhancement will be accomplished by: (1) modifying antibodies with chromophores that absorb visible light; and (2) adding antibody binding peptides modified with chromophores that absorb visible light. The combination of Nicoya's LSPR technology and the Wylie lab's expertise in therapeutic antibodies will result in the development of new LSPR protocols and materials to rapidly analyze dilute antibody solutions.*